The BioPharm Brief: Biosimilars, Obesity Deals, and Crohn Disease Data

Oct 13, 08:55 PM
Headliner
Share
Subscribe

FDA reviews a proposed Keytruda biosimilar, Roche expands its obesity pipeline with an RNAi deal, and guselkumab shows promise for fistula remission in Crohn disease.

Share
Subscribe
Next
The BioPharm Brief: Trials Test CAR-T, Immunology and Targeted Oncology
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief